Skip to main content

16 Result(s)

within A M Bergman Remove this filter

and

  1. No Access

    Article

    The effects of new life-prolonging drugs for metastatic castration-resistant prostate cancer (mCRPC) patients in a real-world population

    In 2004 docetaxel was the first life-prolonging drug (LPD) registered for metastatic castration-resistant prostate cancer (mCRPC) patients. Between 2011 and 2014 new LPDs for mCRPC (cabazitaxel, abiraterone, e...

    H. M. Westgeest, M. C. P. Kuppen… in Prostate Cancer and Prostatic Diseases (2021)

  2. No Access

    Article

    Exposure–response analyses of abiraterone and its metabolites in real-world patients with metastatic castration-resistant prostate cancer

    Abiraterone acetate is an oral 17α-hydroxylase/C17,20-lyase (CYP17) inhibitor approved for the treatment of metastatic castration-resistant prostate cancer (mCPRC) patients. Previously, a prospective observati...

    M. van Nuland, S. L. Groenland, A. M. Bergman… in Prostate Cancer and Prostatic Diseases (2020)

  3. No Access

    Article

    Endogenous androgen receptor proteomic profiling reveals genomic subcomplex involved in prostate tumorigenesis

    Androgen receptor (AR) is a key player in prostate cancer development and progression. Here we applied immunoprecipitation mass spectrometry of endogenous AR in LNCaP cells to identify components of the AR tra...

    S Stelloo, E Nevedomskaya, Y Kim, L Hoekman, O B Bleijerveld, T Mirza… in Oncogene (2018)

  4. No Access

    Article

    22 Neoadjuvante dose-dense MVAC voor spierinvasief blaascarcinoom

    Neoadjuvante cisplatinehoudende chemotherapie voor spierinvasief blaascarcinoom resulteert bij 30- 40% van de patiënten tot complete pathologische respons (CPR) en een betere overleving dan cystectomie alleen.

    E.E. Fransen van de Putte, L.S. Mertens, R.P. Meijer… in Tijdschrift voor Urologie (2014)

  5. No Access

    Article

    19 Inductiechemotherapie en chirurgie bij klierpositief blaascarcinoom

    R.P. Meijer, L.S. Mertens, B.W. van Rhijn, A. Bex… in Tijdschrift voor Urologie (2013)

  6. No Access

    Article

    3 Waarde van PET-CT bij spierinvasief blaascarcinoom

    L.S. Mertens, M.C. Mir, A. Fioole-Bruining, R. Manecksha… in Tijdschrift voor Urologie (2013)

  7. No Access

    Article

    11 Neoadjuvante behandeling van locally advanced peniscarcinoom met taxanenbevattende combinatiechemotherapie

    R.S. Djajadiningrat, A.M. Bergman, S. Horenblas in Tijdschrift voor Urologie (2013)

  8. No Access

    Article

    18 Occulte lymfekliermetastasen na neoadjuvante chemotherapie en bij directe radicale cystectomie bij patiënten met klinisch lymfekliernegatief spierinvasief blaascarcinoom

    L.S. Mertens, R.P. Meijer, W. Meinhardt, A. Bex… in Tijdschrift voor Urologie (2013)

  9. No Access

    Article

    Nocturia Now

    Nocturia is a highly prevalent and bothersome condition, associated with serious medical conditions, as well as increased mortality risk. Nonetheless, it remains an underreported, underdiagnosed, and undertrea...

    A. M. Bergman, V. J. Li, J. P. Weiss in Current Bladder Dysfunction Reports (2013)

  10. No Access

    Article

    Neoadjuvante chemotherapie bij lokaal gevorderd en/of naar de lymfeklieren gemetastaseerd blaascarcinoom

    L. S. Mertens, R. P. Meijer, B. W. van Rhijn, J. M. Kerst… in Tijdschrift voor Urologie (2012)

  11. No Access

    Chapter and Conference Paper

    Automatic, Patient-Specific, Monte Carlo Based IMRT QA, without Ionization Chamber or Film

    We present a Monte Carlo based QA process for IMRT that uses both the planning MLC control files and the post-delivery MLC diagnostic files, thereby opening the possibility of performing highly accurate, autom...

    Ioan Antoniu Popescu, A. M. Bergman, W. Kwa in World Congress on Medical Physics and Biom… (2007)

  12. Article

    Open Access

    Increased sensitivity to gemcitabine of P-glycoprotein and multidrug resistance-associated protein-overexpressing human cancer cell lines

    Gemcitabine (2′,2′-difluorodeoxycytidine) is a deoxycytidine analogue that is activated by deoxycytidine kinase (dCK) to its monophosphate and subsequently to its triphosphate dFdCTP, which is incorporated int...

    A M Bergman, H M Pinedo, I Talianidis, G Veerman, W J P Loves… in British Journal of Cancer (2003)

    Download PDF (391 KB) View Article

  13. Article

    Open Access

    Mechanisms of synergism between cisplatin and gemcitabine in ovarian and non-small-cell lung cancer cell lines

    2′,2′-Difluorodeoxycytidine (gemcitabine, dFdC) and cis-diammine-dichloroplatinum (cisplatin, CDDP) are active agents against ovarian cancer and non-small-cell lung cancer (NSCLC). CDDP acts by formation of plati...

    C J A van Moorsel, H M Pinedo, G Veerman, A M Bergman… in British Journal of Cancer (1999)

    Download PDF (364 KB)

  14. No Access

    Chapter

    Mechanisms of Synergism Between Gemcitabine and Cisplatin

    2′,2′-difluorodeoxycytidine (Gemcitabine, dFdC) is an antineoplastic agent with clinical activity against several cancer types.1 cis-Diamminedichloroplatinum (cisplatin, CDDP) is a drug with long established anti...

    C. J. A. van Moorsel, G. Veerman… in Purine and Pyrimidine Metabolism in Man IX (1998)

  15. No Access

    Chapter

    Differential Effects of Gemcitabine on Nucleotide Pools of 19 Solid Tumor Cell Lines

    2,2-Difluorodeoxycytidine (dFdC, Gemcitabine, Gemzar) is a deoxycytidine analogue, which is very active against murine experimental tumor models, human tumor xenografts and in clinical Phase II studies.1'2 After ...

    C. J. A. van Moorsel, G. Veerman… in Purine and Pyrimidine Metabolism in Man IX (1998)

  16. No Access

    Article

    Abstracts of poster presentations

    A. B. Agostinho, F. Rosi, A. Tabucchi, F. Carlucci… in Pharmacy World and Science (1993)